Lineage Cell Therapeutics (STU:BT3) Other Net Income (Loss) : €-0.00 Mil (TTM As of Jun. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Lineage Cell Therapeutics Other Net Income (Loss)?

Lineage Cell Therapeutics's Other Net Income (Loss) for the three months ended in Jun. 2024 was €0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.00 Mil.

Lineage Cell Therapeutics's quarterly Other Net Income (Loss) declined from Dec. 2023 (€0.00 Mil) to Mar. 2024 (€-0.00 Mil) but then increased from Mar. 2024 (€-0.00 Mil) to Jun. 2024 (€0.00 Mil).

Lineage Cell Therapeutics's annual Other Net Income (Loss) increased from Dec. 2021 (€-0.00 Mil) to Dec. 2022 (€0.00 Mil) and increased from Dec. 2022 (€0.00 Mil) to Dec. 2023 (€0.00 Mil).

Lineage Cell Therapeutics Other Net Income (Loss) Historical Data

The historical data trend for Lineage Cell Therapeutics's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Other Net Income (Loss) Chart

Lineage Cell Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Lineage Cell Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Lineage Cell Therapeutics Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00 Mil.

Lineage Cell Therapeutics Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Lineage Cell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (STU:BT3) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

LCTX:USA LCTX:Israel BT3:Germany

Address

2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008

Website

https://www.lineagecell.com

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Lineage Cell Therapeutics Headlines

No Headlines